Second-dose VITT: rare but real

In the current issue of Blood, Krzywicka et al(1) convincingly show for the first time, that vaccine-induced immune thrombocytopenia and thrombosis (VITT) can occur after a second dose of the AstraZeneca/Oxford ChAdOx1 nCoV-19 vaccine.

Automated summary

In the current issue of Blood, Krzywicka et al convincingly demonstrate for the first time that vaccine-induced immune thrombocytopenia and thrombosis (VITT) can occur after a second dose of the AstraZeneca/Oxford ChAdOx1 nCoV-19 vaccine.